Literature DB >> 34787672

Errors in Abstract, Key Points, Figures, and a Table.

.   

Abstract

Entities:  

Year:  2021        PMID： 34787672      PMCID： PMC8600391          DOI： 10.1001/jamadermatol.2021.4442

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  1 in total

1.  Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.

Authors:  Sophie Glatt; Gregor B E Jemec; Seth Forman; Christopher Sayed; George Schmieder; Jamie Weisman; Robert Rolleri; Seth Seegobin; Dominique Baeten; Lucian Ionescu; Christos C Zouboulis; Stevan Shaw
Journal:  JAMA Dermatol       Date:  2021-11-01       Impact factor: 10.282
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.